ArticleEuropean radiology2022
Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of Literature.Annals of surgical oncology · 2023Pooled it
- Application of MR Cytometry in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Comparative Study.Journal of magnetic resonance imaging : JMRI · 2026Article
- AI-assisted digital breast tomosynthesis as a decision-support tool for post-neoadjuvant surgical planning in breast cancer.Langenbeck's archives of surgery · 2026Article
- Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy.European radiology · 2026Article
- Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 1: Locoregional Therapy, Pathology, Radiology.European journal of breast health · 2026Article
- Pretreatment MRI radiomics for predicting pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Longitudinal MRI-based deep learning model for predicting pathological complete response in breast cancer: a multicenter, retrospective cohort study.NPJ precision oncology · 2026Article
- Comparison of diffusion-weighted and contrast-enhanced MRI for monitoring response to neoadjuvant therapy in breast cancer.European radiology · 2025Article
- Can we cut the contrast? DWI shows similar value to standard MRI for assessing treatment response in breast cancer.European radiology · 2025Article
- Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer.NPJ breast cancer · 2025Article
- Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy for Primary Breast Cancer Comparing Interim Shear Wave Elastography Versus Magnetic Resonance Imaging.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2025Observational
- Predicting Pathologic Complete Response Using Breast MRI After Completion of Neoadjuvant Chemotherapy in Breast Cancer Patients With Residual Calcifications on Mammography.Journal of Korean medical science · 2025Article
- Article
- Article
- Article
- Prediction model for individualized precision surgery in breast cancer patients with complete response on MRI and residual calcifications on mammography after neoadjuvant chemotherapy.Breast cancer (Tokyo, Japan) · 2025Article
- Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.Breast cancer research and treatment · 2024Article
- Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy.Breast cancer research and treatment · 2024Article
- Article
- Pre-operative MRI in evaluating pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer: a study focused on influencing factors of baseline clinical-pathological and imaging features.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to investigate the predictability of breast MRI for pathologic complete response (pCR) by molecular subtype in patients with breast cancer receiving neoadjuvant chemotherapy (NAC) and investigate the MRI findings that can mimic residual malignancy.
methodsA total of 506 patients with breast cancer who underwent MRI after NAC and underwent surgery between January and December 2018 were included. Two breast radiologists dichotomized the post-NAC MRI findings as radiologic complete response (rCR) and no-rCR. The diagnostic performance of MRI predicting pCR was evaluated. pCR was determined based on the final pathology reports. Tumors were divided according to hormone receptor (HR) and human epidermal growth factor receptor (HER) 2. Residual lesions on post-NAC MRI were divided into overt and subtle which classified as nodularity or delayed enhancement. Pearson's χ
resultsThe overall pCR rate was 30.04%. The overall accuracy for predicting pCR using MRI was 76.68%. The accuracy was significantly different by subtypes (p < 0.001), as follows in descending order: HR - /HER2 - (85.63%), HR + /HER2 - (82.84%), HR + /HER2 + (69.37%), and HR - /HER2 + (62.38%). MRI in the HR - /HER2 + type showed the highest false-negative rate (18.81%) for predicting pCR. The subtle residual enhancement observed only in the delayed phase was associated with false-negative findings (76.2%, p = 0.016).
conclusionsThe diagnostic accuracy of MRI for predicting pCR differed by molecular subtypes. When the residual enhancement on MRI after NAC is subtle and seen only in the delayed phase, overinterpretation of residual tumors should be performed with caution. KEY POINTS: • In patients with breast cancer after completion of neoadjuvant chemotherapy, the diagnostic accuracy of MRI for predicting pathologic complete response (pCR) differed according to molecular subtype. • When residual enhancement on MRI is subtle and seen only in the delayed phase, this finding could be associated with false-negative pCR results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.